 BOSTON--BUSINESS WIRE--Gamida Cell Ltd. Nasdaq: GMDA, an advanced cell therapy company committed to cures for blood cancers and serious hematologic diseases, today announced that the full results of the Phase 3 clinical trial of omidubicel will be presented for the first time at the TCT Meetings, the Transplantation Cellular Therapy Meetings of the American Society of Transplantation and Cellular Therapy ASTCT and Center for International Blood Marrow Transplant Research CIBM 